.jpg)
Mabloc empowers our partners to push the limits of antibody discovery. With BRAID™, we optimize every phase of development—from discovery and validation to clinical readiness. Our platform is agnostic to therapeutic target areas, enabling us to accelerate timelines and enhance success across a wide variety of diseases. Whether it’s targeting emerging pathogens or unlocking new therapeutic possibilities, we partner with you to bring life-changing treatments to patients faster than ever before.
We start by harvesting a vast library of antibody sequences tailored to your therapeutic target. Using Mabloc’s BRAID™ platform, we generate candidates that are optimized for potency, manufacturability, and adaptability to evolving diseases.
Our AI-driven platform refines these sequences, evaluating thousands of variants simultaneously to improve binding, stability, and scalability. We select the most promising candidates to move forward in development, maximizing their potential for success.
Once the optimized candidates are selected, we test them in non-human primates to ensure safety and effectiveness. This critical step accelerates the path to clinical trials, giving you confidence in the lead candidates' performance before advancing to human studies.
By collaborating with Fiocruz, we gain access to primary viral isolates, which are essential for developing Mabloc’s challenge models.
Mabloc’s roots are connected to professor Dr. Watkins and the University of Miami, providing a strong academic foundation for the company’s early development.
Dr. Watkins’ is a professor at George Washington University, which grants Mabloc access to invaluable resources, such as the GW BSL III Lab.
Through our advisor Dr. Jonah Sacha, Mabloc partners with OHSU’s Vaccine and Gene Therapy Institute, a word leading institution in the fight against global viral threats like AIDS and COVID-19.
Collaborating with the University of Wisconsin’s National Primate Research Center enables us to conduct non-human primate studies, which is critical to the company’s preclinical research.
Through Dr. Justin Julander we have partnered with Utah State University’s Animal, Dairy, and Veterinary Sciences Department to conduct all rodent model experiments.
Our partnership with Dr. Dennis Burton at the Scripps Research Institute has been instrumental in shaping the BRAID™ platform for antibody discovery and development.
In collaboration with Dr. Esper Kallas, Mabloc has partnered with the University of São Paulo, Brazil’s leading clinical trials site, where Mabloc’s upcoming mAb clinical trials will be conducted.
"At Mabloc, we’re focused on one thing: making sure our therapies reach people as soon as possible. With BRAID™, we’re not waiting around for years—we’re pushing to get life-saving treatments into the hands of those who need them, now. I always tell my team, ‘We’re doing this today, not in some distant future.’ That’s what drives us every day.”
